Department of Error

Blevins T, Dahl D, Pérez Manghi FC, et al. Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. Lancet 2025; 405: 2290–301—In this Article, the appendix file has been updated; the appendix citations to p 139 have been corrected to p 147 in the final sentence of the first paragraph of the Study design and participants section of the Methods, the first sentence of the fourth paragraph of the Statistical analysis section of the Methods, and the final sentence of the eighth paragraph of the Statistical analysis section of the Methods; the sentence “The protocol was amended after study initiation to include the Diabetes Injection Device Experience Questionnaire to align with regulatory requirements for the collection of information regarding the user experience with the device” has been added to the final paragraph of the Outcomes section in the Methods; and corrections to the y-axis labels and units for week 26 data have been made to figure 3D. These corrections have been made to the online version as of Oct 2, 2025.